Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEULARK phase 2 study of NEU-411 in companion diagnostic-positive early Parkinson's disease
2024-515448-22-00Phase 2Authorised
- Sponsor
- Neuron23
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of NEU-411 in Parkinson's disease (PD) (3 arms), sponsored by Neuron23. Planned start Mar 2026; status: authorised.
02
Drugs
NEU-411
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-515448-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515448-22-00.